In addition to the Director and Deputy Director, the senior leadership of DF/HCC includes nine Associate Directors and thirteen Deputy Associate Directors (some of whom serve in more than one role). The Associate Directors have oversight and coordination responsibility for: Basic Science, Clinical Science, Population Science, Core Facilities, Planning and Evaluation, Development, Membership, and Administration. The Deputy Associate Director assists the respective Associate Director in his/her duties and is available to assume these duties should the Associate Director be unable to serve. These senior leaders meet every other week as the DF/HCC Executive Committee (EC), whose functions are described in Section 6.0 Organizational Capabilities. Six of these individuals also serve as Institutional Representatives. Dr. Fred Alt is the Institutional Representative for Children's Hospital Boston but does not currently serve as an Associate Director or Deputy Associate Director for the DF/HCC. Dr. Alt does participate as a member of the Executive Committee. Since the seven independent institutions participating in DF/HCC have different cultures as well as different locations, the primary responsibility of the Institutional Representative is for communication. In particular, they insure that the DF/HCC members within their institutions are aware of all activities, policies and procedures of the Cancer Center, and that the Center leadership is made aware of any issues from their institution. In addition, they are responsible for the day-to-day representation of the interests of DF/HCC at their institution, and the interests of their institution within DF/HCC. (Members of the Governance Committee have the ultimate responsibility for such institutional interests.)

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006516-46
Application #
8038406
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-12-01
Budget End
2010-11-30
Support Year
46
Fiscal Year
2010
Total Cost
$570,294
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
McBrayer, Samuel K; Mayers, Jared R; DiNatale, Gabriel J et al. (2018) Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma. Cell 175:101-116.e25
Stopsack, Konrad H; Gonzalez-Feliciano, Amparo G; Peisch, Samuel F et al. (2018) A Prospective Study of Aspirin Use and Prostate Cancer Risk by TMPRSS2:ERG Status. Cancer Epidemiol Biomarkers Prev 27:1231-1233
Kamareddine, Layla; Wong, Adam C N; Vanhove, Audrey S et al. (2018) Activation of Vibrio cholerae quorum sensing promotes survival of an arthropod host. Nat Microbiol 3:243-252
Schilit, Samantha L P; Morton, Cynthia C (2018) 3C-PCR: a novel proximity ligation-based approach to phase chromosomal rearrangement breakpoints with distal allelic variants. Hum Genet 137:55-62
Sievers, Quinlan L; Gasser, Jessica A; Cowley, Glenn S et al. (2018) Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4CRBN activity. Blood 132:1293-1303
Kelley, Katherine A; Wieghard, Nicole; Chin, Yuki et al. (2018) MiR-486-5p Downregulation Marks an Early Event in Colorectal Carcinogenesis. Dis Colon Rectum 61:1290-1296
Yao, Lina; Seaton, Sarah Craven; Ndousse-Fetter, Sula et al. (2018) A selective gut bacterial bile salt hydrolase alters host metabolism. Elife 7:
Jalbut, Marla M; Brunner, Andrew M; Amrein, Philip C et al. (2018) Early infectious complications among patients treated with induction compared to hypomethylating therapy for acute myeloid leukemia. Leuk Lymphoma 59:988-991
Tapela, Neo M; Peluso, Michael J; Kohler, Racquel E et al. (2018) A Step Toward Timely Referral and Early Diagnosis of Cancer: Implementation and Impact on Knowledge of a Primary Care-Based Training Program in Botswana. Front Oncol 8:187
Roemer, Margaretha G M; Redd, Robert A; Cader, Fathima Zumla et al. (2018) Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. J Clin Oncol 36:942-950

Showing the most recent 10 out of 411 publications